Jose Antonio Lopez-Vilarino de Ramos

ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.

L. Paz-Ares, C. Galmarini, A. Farago, 2019, Future oncology.